Online inquiry

IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15762MR)

This product GTTS-WQ15762MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CA9 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001216.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15762MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1858MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ1600MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ10791MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ4659MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ8107MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ12955MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ12516MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ2534MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW